Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability, and Pharmacokinetics of Lasmiditan in Healthy Chinese Subjects

NCT04081324 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04081324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04081324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability, and Pharmacokinetics of Lasmiditan in Healthy Chinese Subjects
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
November 13, 2019
Completion date
June 15, 2020
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy